Ferumoxytol

New form of intravenous iron treats anemia in chronic kidney disease patients on dialysis

...ective alternative to other forms of iron therapy. ferumoxytol appears to contain less free iron and be less immu...nducted a phase three clinical trial that compared ferumoxytol with oral iron. The trial enrolled 230 anemic pati... Patients received either two injections of 510 mg ferumoxytol within seven days or 200 mg oral iron daily for 21...

Satellite Healthcare Will Present at the American Society of Nephrology's Renal Week – Booth 527 : November 4-9, 2008

...ing Thrice Weekly or More Frequent HD presented by Bhupinder Virk, MD; Sheila Doss, RN; John Moran, MB, BS; Brigitte Schiller, MD Efficacy of IV ferumoxytol in CKD Patients with Persistent Anemia Despite Oral Iron Therapy presented by Brigitte Schiller, MD: Paul Miller, Jiannong Liu, Robert Brenner and Rob...

Ferumoxytol in Medical Technology

Advanced Magnetics Announces Presentation of Ferumoxytol Data at the National Kidney Foundation 2007 Spring Clinical Meetings

CAMBRIDGE, Mass., March 06, 2007 /PRNewswire-FirstCall/ -- Advanced Magnetics today announced that data from three completed Phase III multi- center clinical studies of ferumoxytol as an intravenous iron replacement therapeutic will be presented during the National Kidney Foundation (NKF) 2007 Spr...

Advanced Magnetics Announces Positive Results from Two Additional Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement Therapeutic

CAMBRIDGE, Mass., April 11, 2007 /PRNewswire-FirstCall/ -- Advanced Magnetics today announced positive results from two additional Phase III clinical trials of ferumoxytol as an intravenous (IV) iron replacement therapeutic that are being presented today at approximately 6:00 pm EDT as posters at ...

Ferumoxytol in Biological Technology

AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China

SHENYANG, China, May 28 /Xinhua-PRNewswire-FirstCall/ -- AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG ) and 3SBio, Inc. (Nasdaq: SSRX ), a leading Chinese biotechnology company, today announced the signing of a development and commercialization agreement for ferumoxytol, an intravenous iron repl...

3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results

...hree new product programs; 36,000 IU dosage formulation of EPIAO, NuLeusin, and TPIAO label extension for the treatment of ITP. -- Initiate ferumoxytol registration trial in China, following US FDA approval. -- Submit application for clinical trials of NuPIAO, the Company's second ge...

BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...Venofer to increase following the news that Fresenius will be marketing and distributing Venofer in dialysis units. Awareness of AMAG Pharmaceutical's ferumoxytol continues to be low. Among those familiar with the product, expected benefits center around dosing and administration, particularly for CKD patients. ...

3SBio Inc. Announces Second Quarter 2008 Results

...ess on the business development front, notably, the initiation of a strategic partnership with AMAG Pharmaceuticals, Inc. to develop and commercialize ferumoxytol and the rapid progression of our phase III programs in our portfolio." Second Quarter 2008 Unaudited Financial Results Net Revenues. Our net reven...

BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...e products to be differentiated, Venofer tends to have a perceived advantage on ease of administration in both dialysis and CKD. AMAG Pharmaceutical's ferumoxytol could be commercially available by the end of the year. Those with higher familiarity of the product, feel it has a dosing and administration advantag...

BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...led an NDA for a new form of intravenous iron, ferumoxytol, which could be commercially available in the second half of 2008. Current familiarity with ferumoxytol is low, with 68% indicating that they are "not at all familiar" with the product. In the phosphate binder market, nephrologists seem to be in agreem...